Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
reproductive health
Biotech
Ferring terminates fertility trials after ‘portfolio assessment’
Two trials testing the pairing of choriogonadotropin beta with Rekovelle have been terminated as part of “a broader portfolio assessment.”
Darren Incorvaia
Apr 2, 2026 2:00pm
Organon pays $27.5M upfront for Sebela's hormone-free copper IUD
Feb 24, 2026 4:25am
PacBio launches carrier screening panel in reproductive health
Sep 22, 2025 11:00am
Take 2: CooperSurgical pays $300M for Cook Medical assets
Nov 3, 2023 10:28am
Ferring's research site closure signals shift from internal R&D
Apr 11, 2023 11:22am
Sema4 lays off 448 employees, exits reproductive health testing
Nov 18, 2022 10:42am
